Ab1271 Evaluation of Sinonasal Involvement in Anca-Associated Vasculitis Using the Snot-22 Questionnaire

Background: Anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) constitutes a diverse group of diseases characterized by inflammatory damage to small to medium-sized vessels, leading to organ and tissue impairment. Along with pulmonary and renal, upper airway involvement is a common feature, especially for granulomatosis with polyangiitis. The Sinonasal Outcome Test 22 (SNOT-22) is a 22-item questionnaire that combines both nasal and general health symptoms, providing a quantitative measurement of the severity of various symptoms related to chronic rhinosinusitis, with each question scored on a scale of 0 to 5 and a total possible score of 110. It has been widely used and validated for assessing disease-specific outcomes and quality of life in patients with sinonasal conditions. Objectives: Primary objective of this study was to utilize the SNOT-22 questionnaire to evaluate sinonasal symptoms in AAV patients. Methods: AAV patients followed in Gazi University outpatient rheumatology clinic between January and December 2023 were included in the study. During their routine follow-up, SNOT-22 was administered to all consenting patients. Information regarding demographic, clinical and laboratory was extracted from patient files. Results: A total of 90 AAV patients were included in the study, with a mean age of diagnosis at 47.8 ± 14.4 years. The majority of patients were female (53%) GPA was the predominant diagnosis (75.6). 61 patients (68%) had upper respiratory tract symptoms. ANCA patterns revealed c-ANCA in 55.2% and p-ANCA in 20.7%. Mean BVAS score at the time of diagnosis was 18,3 and median FFS score was 1,0 (Table 1). At the time of SNOT-22 administration, patients had a mean age of 53.7 ± 13.5 years. 35 patients (38.9%) had upper respiratory tract findings, with most common being sensorineural hearing loss in 21.1%. Median CRP was 5,1 mg/L (IQR: 6,9). Most patients were at remission (median BVAS: 0). SNOT-22 median score (IQR) was 0 (4), with 37.8% of patients having a score greater than 0; categorically, 62.2% scored 0, 10% scored 1–3, 14.4% scored 4–9, and 13.3% scored ≥10 (Table 2). There was no difference between SNOT-22 score and demographic, clinical and laboratory findings. Conclusion: SNOT-22 has the potential to be used as a patient reported outcome tool in AAV patients. Further research is needed to confirm this prospectively. REFERENCES: NIL. Acknowledgements: NIL. Disclosure of Interests: None declared.